

CLAIM AMENDMENTS:

1. (previously cancelled)
2. (previously cancelled)
3. (previously cancelled)
4. (previously cancelled)
5. (previously cancelled)
6. (currently amended) A method of treating a human

immunodeficiency virus (HIV) infection comprising:

reducing HIV virus load or reducing HIV virus particle formation in
an individual by administering an effective amount of a pharmaceutical
composition comprising Xestospongin C (XeC) to an said individual in need of
said treatment.

7. (previously cancelled)
8. (previously cancelled)
9. (previously cancelled)
10. (previously cancelled)
11. (previously cancelled)
12. (previously cancelled)
13. (previously cancelled)
14. (previously cancelled)
15. (previously cancelled)
16. (previously cancelled)
17. (previously cancelled)

18. (previously cancelled)

19. (previously cancelled)

20. (previously cancelled)

21. (previously cancelled)

22. (previously cancelled)

23. (previously cancelled)

24. (previously cancelled)

25. (previously cancelled)

26. (previously cancelled)

27. (previously cancelled)

28. (previously cancelled)

29. (previously cancelled)

30. (previously cancelled)

31. (previously cancelled)

32. (previously presented) The method according to claim 6

wherein the XeC is administered at a concentration between 0.1 μ M to 100 μ M.

33. (previously presented) The method according to claim 6

wherein the XeC is administered at a dosage between 0.1 μ g to 10 mg.

34. (currently amended) The method according to claim 6

wherein the XeC is administered in combination with an effective amount of at least one of the following selected from the group consisting of azidothymidine, lamivudine, dideoxyinosidine, ritonavir, an HIV protease inhibitor and an HIV reverse transcriptase inhibitor.

35. (new) The method according to claim 32 wherein the XeC is administered at a concentration between 0.1 μ M to 10 μ M.

36. (new) The method according to claim 35 wherein the XeC is administered at a concentration between 1 μ M to 10 μ M.

37. (new) The method according to claim 32 wherein the XeC is administered at a concentration between 1 μ M to 100 μ M.